The impact of chromosomal fusions on 3D genome
The influence of chromosomal fusions on 3D genome folding and recombination within the germ line
The spatial folding of chromosomes contained in the nucleus has regulatory results on gene expression, but the influence of genome reshuffling on this group stays unclear. Right here, we make the most of chromosome conformation seize together with single-nucleotide polymorphism (SNP) genotyping and evaluation of crossover occasions to review how the higher-order chromatin group and recombination landscapes are affected by chromosomal fusions within the mammalian germ line.
We exhibit that chromosomal fusions alter the nuclear structure throughout meiosis, together with an elevated price of heterologous interactions in main spermatocytes, and alterations in each chromosome synapsis and axis size.
These disturbances in topology have been related to modifications in genomic landscapes of recombination, leading to detectable genomic footprints. General, we present that chromosomal fusions influence the dynamic genome topology of germ cells in two methods: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.
Profiles of immune cell infiltration and immune-related genes within the tumor microenvironment of HNSCC with or with out HPV an infection
Head and neck squamous cell carcinoma (HNSCC) are the sixth commonest most cancers sort on this planet. Human papillomavirus (HPV) an infection is an rising threat issue for HNSCC. Immune infiltration of HNSCC is linked to therapeutic outcomes. This text aimed to determine whether or not variations in HPV standing have an effect on immune infiltration, molecular mechanism, and the way these outcomes fluctuate in HNSCC sufferers.
We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene variations between HPV (+) and HPV (-) HNSCC. The gene expression quantification information of HNSCC and their medical data have been obtain from the TCGA database. Immune-related genes have been linked to the ImmPort platform.
After analyzed of 22 TIICs within the HNSCC tumor atmosphere by CIBERSORT and additional evaluation, decrease reminiscence B cell and better T cell regulatory have been related with higher HPV (-) HNSCC end result, increased activated reminiscence CD4 T cell, increased T cell regulatory, and decrease activated NK cell have been linked with higher HPV (+) consequence.
We lastly acquired 5 types of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) related to HNSCC development. Larger expressions of CAMP, EDNRB, and NTS have been related to elevated total survival in HPV (-) sufferers. Larger expression of CXCL9 and decrease expression of LHB contributed to elevated total survival of HPV (+) sufferers.
There are typically discrepancies within the cell construction of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are usually too essential for the therapeutic end result of the affected person and the event of the tumor. In particular, our pattern established these candidate immune cells and immune-related genes as candidate reservoirs for additional researches.

Tie2 Kinase Inhibitor |
|||
B1338-5 | Biovision | each | EUR 314.4 |
Tie2 kinase inhibitor |
|||
A5979-100 | ApexBio | 100 mg | EUR 1452 |
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38. |
Tie2 kinase inhibitor |
|||
A5979-25 | ApexBio | 25 mg | EUR 477.6 |
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38. |
Tie2 kinase inhibitor |
|||
A5979-5 | ApexBio | 5 mg | EUR 199.2 |
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38. |
Tie2 kinase inhibitor |
|||
A5979-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 536.4 |
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38. |
Tie2 kinase inhibitor |
|||
E1KS1577 | EnoGene | 10mg | EUR 1849.2 |
K252A (Kinase inhibitor) |
|||
SIH-455-100UG | Stressmarq | 100 µg | EUR 157.2 |
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO. |
K252A (Kinase inhibitor) |
|||
SIH-455-1MG | Stressmarq | 1 mg | EUR 358.8 |
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO. |
K252B (Kinase inhibitor) |
|||
SIH-456-100UG | Stressmarq | 100 µg | EUR 218.4 |
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml). |
K252B (Kinase inhibitor) |
|||
SIH-456-1MG | Stressmarq | 1 mg | EUR 682.8 |
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml). |
MAPKII Kinase Inhibitor |
|||
abx076811-1mg | Abbexa | 1 mg | EUR 376.8 |
Sorafenib (Raf-1 kinase inhibitor) |
|||
SIH-476-10MG | Stressmarq | 10 mg | EUR 145.2 |
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml). |
Sorafenib (Raf-1 kinase inhibitor) |
|||
SIH-476-50MG | Stressmarq | 50 mg | EUR 346.8 |
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml). |
Tyrosine kinase inhibitor |
|||
HY-10421 | MedChemExpress | 25mg | EUR 459.6 |
Dasatinib (Kinase inhibitor) |
|||
SIH-440-25MG | Stressmarq | 25 mg | EUR 238.8 |
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ). |
Dasatinib (Kinase inhibitor) |
|||
SIH-440-5MG | Stressmarq | 5 mg | EUR 160.8 |
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ). |
IKK-? Kinase Inhibitor II |
|||
1811-1 | Biovision | each | EUR 189.6 |
IKK-? Kinase Inhibitor II |
|||
1811-5 | Biovision | each | EUR 574.8 |
RIP2 kinase inhibitor 2 |
|||
HY-19761 | MedChemExpress | 50mg | EUR 2539.2 |
PP1 (Src kinase inhibitor) |
|||
SIH-469-25MG | Stressmarq | 25 mg | EUR 742.8 |
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol. |
PP1 (Src kinase inhibitor) |
|||
SIH-469-5MG | Stressmarq | 5 mg | EUR 246 |
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol. |
PP2 (Src kinase inhibitor) |
|||
SIH-470-25MG | Stressmarq | 25 mg | EUR 884.4 |
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml). |
PP2 (Src kinase inhibitor) |
|||
SIH-470-5MG | Stressmarq | 5 mg | EUR 279.6 |
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml). |
C16 (PKR kinase inhibitor) |
|||
SIH-498-25MG | Stressmarq | 25 mg | EUR 420 |
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml . |
C16 (PKR kinase inhibitor) |
|||
SIH-498-5MG | Stressmarq | 5 mg | EUR 164.4 |
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml . |
Midostaurin (Kinase inhibitor) |
|||
SIH-468-1MG | Stressmarq | 1 mg | EUR 205.2 |
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml). |
Midostaurin (Kinase inhibitor) |
|||
SIH-468-5MG | Stressmarq | 5 mg | EUR 608.4 |
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml). |
Aurora Kinase Inhibitor 3 |
|||
HY-112373 | MedChemExpress | 1mg | EUR 198 |
6BIO (PDK1 kinase inhibitor) |
|||
SIH-422-25MG | Stressmarq | 25 mg | EUR 474 |
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol. |
6BIO (PDK1 kinase inhibitor) |
|||
SIH-422-5MG | Stressmarq | 5 mg | EUR 178.8 |
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol. |
LYS6K2 (S6 kinase inhibitor) |
|||
SIH-462-25MG | Stressmarq | 25 mg | EUR 582 |
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming). |
LYS6K2 (S6 kinase inhibitor) |
|||
SIH-462-5MG | Stressmarq | 5 mg | EUR 205.2 |
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming). |
Aurora Kinase Inhibitor III |
|||
B7947-.5 | ApexBio | 500 µg | EUR 141.6 |
Description: Aurora Kinase Inhibitor III |
Aurora Kinase Inhibitor III |
|||
B7947-1 | ApexBio | 1 mg | EUR 214.8 |
Description: Aurora Kinase Inhibitor III |
Aurora Kinase Inhibitor III |
|||
B7947-5 | ApexBio | 5 mg | EUR 714 |
Description: Aurora Kinase Inhibitor III |
KT5720 (PKA kinase inhibitor) |
|||
SIH-457-100UG | Stressmarq | 100 µg | EUR 246 |
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml. |
KT5720 (PKA kinase inhibitor) |
|||
SIH-457-500UG | Stressmarq | 500 µg | EUR 682.8 |
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml. |
ml167 (Clk4 kinase inhibitor) |
|||
SIH-505-25MG | Stressmarq | 25 mg | EUR 608.4 |
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear . |
ml167 (Clk4 kinase inhibitor) |
|||
SIH-505-5MG | Stressmarq | 5 mg | EUR 205.2 |
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear . |
GW2580 (cFMS kinase inhibitor) |
|||
SIH-449-25MG | Stressmarq | 25 mg | EUR 447.6 |
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) . |
GW2580 (cFMS kinase inhibitor) |
|||
SIH-449-5MG | Stressmarq | 5 mg | EUR 168 |
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) . |
PD98059 (MEK kinase inhibitor) |
|||
SIH-466-25MG | Stressmarq | 25 mg | EUR 514.8 |
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml). |
PD98059 (MEK kinase inhibitor) |
|||
SIH-466-5MG | Stressmarq | 5 mg | EUR 184.8 |
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml). |
AZD6244 (ERK kinase inhibitor) |
|||
SIH-495-25MG | Stressmarq | 25 mg | EUR 716.4 |
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
AZD6244 (ERK kinase inhibitor) |
|||
SIH-495-5MG | Stressmarq | 5 mg | EUR 252 |
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
SRPIN340 (SR kinase inhibitor) |
|||
SIH-514-25MG | Stressmarq | 25 mg | EUR 481.2 |
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl. |
SRPIN340 (SR kinase inhibitor) |
|||
SIH-514-5MG | Stressmarq | 5 mg | EUR 178.8 |
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl. |
AG1296 (PDGFR kinase inhibitor) |
|||
SIH-426-25MG | Stressmarq | 25 mg | EUR 608.4 |
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane. |
AG1296 (PDGFR kinase inhibitor) |
|||
SIH-426-5MG | Stressmarq | 5 mg | EUR 205.2 |
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane. |
SU1498 (VEGFR kinase inhibitor) |
|||
SIH-480-25MG | Stressmarq | 25 mg | EUR 447.6 |
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO . |
SU1498 (VEGFR kinase inhibitor) |
|||
SIH-480-5MG | Stressmarq | 5 mg | EUR 169.2 |
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO . |
PD325901 (MEK kinase inhibitor) |
|||
SIH-507-25MG | Stressmarq | 25 mg | EUR 554.4 |
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO. |
PD325901 (MEK kinase inhibitor) |
|||
SIH-507-5MG | Stressmarq | 5 mg | EUR 205.2 |
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO. |
PHA 665752 (MET kinase inhibitor) |
|||
SIH-421-25MG | Stressmarq | 25 mg | EUR 696 |
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. . |
PHA 665752 (MET kinase inhibitor) |
|||
SIH-421-5MG | Stressmarq | 5 mg | EUR 231.6 |
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. . |
A83 01 (ALK kinase inhibitor) |
|||
SIH-423-25MG | Stressmarq | 25 mg | EUR 514.8 |
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO. |
A83 01 (ALK kinase inhibitor) |
|||
SIH-423-5MG | Stressmarq | 5 mg | EUR 187.2 |
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO. |
CID 2011756 (PKD kinase inhibitor) |
|||
SIH-438-25MG | Stressmarq | 25 mg | EUR 514.8 |
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO. |
CID 2011756 (PKD kinase inhibitor) |
|||
SIH-438-5MG | Stressmarq | 5 mg | EUR 184.8 |
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO. |
KT 5823 (PKG kinase inhibitor) |
|||
SIH-458-100UG | Stressmarq | 100 µg | EUR 246 |
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml). |
KT 5823 (PKG kinase inhibitor) |
|||
SIH-458-500UG | Stressmarq | 500 µg | EUR 682.8 |
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml). |
NPC 15437 (PKC kinase inhibitor) |
|||
SIH-464-1MG | Stressmarq | 1 mg | EUR 205.2 |
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol. |
NPC 15437 (PKC kinase inhibitor) |
|||
SIH-464-5MG | Stressmarq | 5 mg | EUR 447.6 |
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol. |
Src I1 (Src kinase inhibitor) |
|||
SIH-478-25MG | Stressmarq | 25 mg | EUR 399.6 |
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml). |
Src I1 (Src kinase inhibitor) |
|||
SIH-478-5MG | Stressmarq | 5 mg | EUR 158.4 |
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml). |
GF109203X (PKC kinase inhibitor) |
|||
SIH-447-10MG | Stressmarq | 10 mg | EUR 306 |
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well). |
GF109203X (PKC kinase inhibitor) |
|||
SIH-447-1MG | Stressmarq | 1 mg | EUR 178.8 |
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well). |
Auranofin (IKK kinase inhibitor) |
|||
SIH-493-50MG | Stressmarq | 50 mg | EUR 178.8 |
Description: The substance Auranofin is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (5 mg/ml) or 100% ethanol (4 mg/ml). |
LY364947 (ALK5 kinase inhibitor) |
|||
SIH-504-25MG | Stressmarq | 25 mg | EUR 474 |
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO. |
LY364947 (ALK5 kinase inhibitor) |
|||
SIH-504-5MG | Stressmarq | 5 mg | EUR 184.8 |
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO. |
p21/Cyclin-Dependent Kinase Inhibitor 1 |
|||
MO47036 | Neuromics | 100 ul | EUR 418.8 |
AG 1478 (EGFR kinase inhibitor) |
|||
SIH-425-25MG | Stressmarq | 25 mg | EUR 474 |
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml). |
AG 1478 (EGFR kinase inhibitor) |
|||
SIH-425-5MG | Stressmarq | 5 mg | EUR 184.8 |
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml). |
AG 1517 (EGFR kinase inhibitor) |
|||
SIH-427-25MG | Stressmarq | 25 mg | EUR 541.2 |
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO. |
AG 1517 (EGFR kinase inhibitor) |
|||
SIH-427-5MG | Stressmarq | 5 mg | EUR 192 |
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO. |
AG 879 (NGFR kinase inhibitor) |
|||
SIH-429-25MG | Stressmarq | 25 mg | EUR 514.8 |
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml). |
AG 879 (NGFR kinase inhibitor) |
|||
SIH-429-5MG | Stressmarq | 5 mg | EUR 182.4 |
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml). |
Bml 277 (CHK2 kinase inhibitor) |
|||
SIH-436-10MG | Stressmarq | 10 mg | EUR 210 |
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml). |
Bml 277 (CHK2 kinase inhibitor) |
|||
SIH-436-50MG | Stressmarq | 50 mg | EUR 608.4 |
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml). |
GW 441756 (NGFR kinase inhibitor) |
|||
SIH-450-10MG | Stressmarq | 10 mg | EUR 279.6 |
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO. |
GW 441756 (NGFR kinase inhibitor) |
|||
SIH-450-50MG | Stressmarq | 50 mg | EUR 877.2 |
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO. |
LFM A13 (BTK kinase inhibitor) |
|||
SIH-461-25MG | Stressmarq | 25 mg | EUR 481.2 |
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml). |
LFM A13 (BTK kinase inhibitor) |
|||
SIH-461-5MG | Stressmarq | 5 mg | EUR 178.8 |
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml). |
Y 27632 (ROCK kinase inhibitor) |
|||
SIH-486-1MG | Stressmarq | 1 mg | EUR 178.8 |
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble. |
Y 27632 (ROCK kinase inhibitor) |
|||
SIH-486-5MG | Stressmarq | 5 mg | EUR 393.6 |
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble. |
AG 494 (EGFR kinase inhibitor) |
|||
SIH-491-10MG | Stressmarq | 10 mg | EUR 178.8 |
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml). |
AG 494 (EGFR kinase inhibitor) |
|||
SIH-491-50MG | Stressmarq | 50 mg | EUR 481.2 |
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml). |
SR 3576 (JNK3 kinase inhibitor) |
|||
SIH-513-5MG | Stressmarq | 5 mg | EUR 298.8 |
Description: The substance SR 3576 is a jnk3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off white solid which is soluble to 100 mM in DMSO. |
CHIR99021 (GSK3? kinase inhibitor) |
|||
SIH-437-1MG | Stressmarq | 1 mg | EUR 151.2 |
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO. |
CHIR99021 (GSK3? kinase inhibitor) |
|||
SIH-437-5MG | Stressmarq | 5 mg | EUR 246 |
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO. |
Gefitinib (EGFR Kinase inhibitor) |
|||
SIH-445-250MG | Stressmarq | 250 mg | EUR 360 |
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C). |
Gefitinib (EGFR Kinase inhibitor) |
|||
SIH-445-50MG | Stressmarq | 50 mg | EUR 164.4 |
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C). |
Axitinib (VEGFR kinase inhibitor) |
|||
SIH-494-10MG | Stressmarq | 10 mg | EUR 346.8 |
Description: The substance Axitinib is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to tan powder which is soluble to 25 mM in DMSO. |
Casein Kinase II Inhibitor IV |
|||
HY-111378 | MedChemExpress | 10mM/1mL | EUR 590.4 |
STO 609 (CAMKK kinase inhibitor) |
|||
SIH-479-25MG | Stressmarq | 25 mg | EUR 474 |
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml). |
STO 609 (CAMKK kinase inhibitor) |
|||
SIH-479-5MG | Stressmarq | 5 mg | EUR 181.2 |
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml). |
ZM 306416 (VEGFR kinase inhibitor) |
|||
SIH-487-25MG | Stressmarq | 25 mg | EUR 474 |
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml). |
ZM 306416 (VEGFR kinase inhibitor) |
|||
SIH-487-5MG | Stressmarq | 5 mg | EUR 178.8 |
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml). |
Ruxolitinib (JAK kinase inhibitor) |
|||
SIH-509-25MG | Stressmarq | 25 mg | EUR 750 |
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml). |
Ruxolitinib (JAK kinase inhibitor) |
|||
SIH-509-5MG | Stressmarq | 5 mg | EUR 285.6 |
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml). |
AG490 (JAK-2 kinase inhibitor) |
|||
SIH-428-25MG | Stressmarq | 25 mg | EUR 339.6 |
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml). |
AG490 (JAK-2 kinase inhibitor) |
|||
SIH-428-5MG | Stressmarq | 5 mg | EUR 158.4 |
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml). |
WHI P131 (JAK3 kinase inhibitor) |
|||
SIH-485-10MG | Stressmarq | 10 mg | EUR 178.8 |
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml). |
WHI P131 (JAK3 kinase inhibitor) |
|||
SIH-485-50MG | Stressmarq | 50 mg | EUR 460.8 |
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml). |
Apigenin (Protein kinase inhibitor) |
|||
SIH-249-10MG | Stressmarq | 10 mg | EUR 127.2 |
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO. |
Apigenin (Protein kinase inhibitor) |
|||
SIH-249-50MG | Stressmarq | 50 mg | EUR 255.6 |
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO. |
ATM Kinase Inhibitor, KU-55933 |
|||
1685-5 | Biovision | each | EUR 288 |
Adenosine Kinase Inhibitor (hydrate) |
|||
C5282-1 | ApexBio | 1 mg | EUR 134.4 |
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations. |
Adenosine Kinase Inhibitor (hydrate) |
|||
C5282-10 | ApexBio | 10 mg | EUR 435.6 |
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations. |
Adenosine Kinase Inhibitor (hydrate) |
|||
C5282-5 | ApexBio | 5 mg | EUR 360 |
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations. |
Diacylglycerol Kinase Inhibitor I |
|||
50R-R59022 | Fitzgerald | 50 mg | EUR 289.2 |
Description: Diacylglycerol Kinase Inhibitor I chemical reference substance |
Dorsomorphin (AMPK kinase inhibitor) |
|||
SIH-443-25MG | Stressmarq | 25 mg | EUR 514.8 |
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm). |
Dorsomorphin (AMPK kinase inhibitor) |
|||
SIH-443-5MG | Stressmarq | 5 mg | EUR 184.8 |
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm). |
Imatinib mesylate (Kinase inhibitor) |
|||
SIH-453-100MG | Stressmarq | 100 mg | EUR 279.6 |
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear . |
Imatinib mesylate (Kinase inhibitor) |
|||
SIH-453-20MG | Stressmarq | 20 mg | EUR 151.2 |
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear . |
BAY 11 7082 (IKK kinase inhibitor) |
|||
SIH-434-10MG | Stressmarq | 10 mg | EUR 184.8 |
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO. |
BAY 11 7082 (IKK kinase inhibitor) |
|||
SIH-434-50MG | Stressmarq | 50 mg | EUR 507.6 |
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO. |
PX 866 (PI 3-Kinase inhibitor) |
|||
SIH-471-1MG | Stressmarq | 1 mg | EUR 178.8 |
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water. |
PX 866 (PI 3-Kinase inhibitor) |
|||
SIH-471-5MG | Stressmarq | 5 mg | EUR 298.8 |
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water. |
LY 294002 (PI 3-Kinase inhibitor) |
|||
SIH-252-25MG | Stressmarq | 25 mg | EUR 532.8 |
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO. |
Multi-ancestry genome-wide affiliation examine identifies 27 loci related to measures of hemolysis following blood storage
The evolutionary strain of endemic malaria and different erythrocytic pathogens has formed variation in genes encoding erythrocyte structural and purposeful proteins, influencing responses to hemolytic stress throughout transfusion and illness.
We sought to determine such genetic variants in blood donors by conducting a genome-wide affiliation examine (GWAS) of 12,353 volunteer donors, together with 1,483 African People, 1,477 Asians, and 960 Hispanics, whose saved erythrocytes have been characterised by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.
GWAS revealed 27 important loci (p<5×10-8), many in candidate genes identified to modulate erythrocyte construction, metabolism, and ion channels, together with SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis recognized variants in antioxidant enzymes together with GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.
Genome extensive important loci have been additionally examined for affiliation with the severity of regular state (baseline) in vivo hemolytic anemia in sufferers with sickle cell illness, with affirmation of recognized SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Most of the recognized variants, equivalent to these in G6PD, have beforehand been proven to impair erythrocyte restoration after transfusion, affiliate with anemia, or trigger uncommon Mendelian human hemolytic illnesses.
Candidate SNPs in these genes, particularly in polygenic combos, could have an effect on RBC restoration after transfusion and modulate illness severity in hemolytic illnesses, equivalent to sickle cell illness and malaria.
Incorporating Genomic and Genetic Testing into the Therapy of Metastatic Luminal Breast Most cancers
Background: Therapy of sufferers with luminal metastatic breast most cancers (MBC) has turn out to be much more complicated over the previous few years as molecular profiling has begun to change illness administration. It’s properly accepted that MBC will not be curable however is treatable. Right now we’re capable of delay progression-free survival and partly total survival with focused and extra particular person therapy methods adjusted in keeping with the molecular subtype.
Abstract: Genetic and genomic testing has turn out to be therapeutically related in luminal MBC and is due to this fact an integral part inside the therapy spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable parts in illness administration and the present state-of-the-art in luminal MBC sufferers.
Moreover, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (primarily in secretory breast most cancers) has just lately gained growing consideration. Nonetheless, primarily based on the increasing function of personalised medication, clinicians are actually confronted with substantial new challenges and presumably unsuspected potentialities. The next evaluation summarizes present developments in genetic and genomic testing in luminal MBC.
Key messages: In luminal MBC genomics have turn out to be an integral part inside the spectrum of oncological therapy establishing novel therapeutic services. Additional developments in therapy personalization adjusted in keeping with the molecular subtype ought to turn out to be more and more necessary as a way to improve the progress of de-escalation of chemotherapy in luminal MBC. Nonetheless, primarily based on the increasing function of personalised medication, clinicians are actually confronted with substantial new challenges and presumably unsuspected potentialities.
HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations) |
|||
0801002 | Zeptometrix | 96T | EUR 603 |
HIV-1 p17-p24 recombinant antigen. |
|||
00172-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 p17-p24 recombinant antigen. |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV 1 p24 core recombinant antigen |
|||
00177-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen |
|||
00177-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen. |
|||
00177-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV 1 p24 core recombinant antigen. |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
|||
0801200 | Zeptometrix | 5 X 96T | EUR 2563 |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
|||
801200 | Zeptometrix | 5 X 96 Determinations | EUR 2330 |
HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations) |
|||
801008 | Zeptometrix | 5 X 96 Determinations | EUR 2386 |
HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations) |
|||
0801008 | Zeptometrix | 5 X 96T | EUR 2505 |
Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit |
|||
EH4101 | FN Test | 96T | EUR 571.5 |
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative |
HIV-1 p24 ELISA Kit |
|||
Z7040001 | Biochain | 1 kit | EUR 752 |
HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
00111-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 p17/24/gp120 antigen |
|||
00169-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 p17/24/gp120 antigen |
|||
00169-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 intergase antigen |
|||
00199-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
HIV-1 intergase antigen |
|||
00199-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
HIV-1 p24 Antibody |
|||
20-abx137062 | Abbexa |
|
|
HIV-1 p24 Antibody |
|||
7313-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
|||
7313-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
|||
abx021869-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
abx021870-1mg | Abbexa | 1 mg | EUR 760.8 |
HIV-1 p24 Antibody |
|||
abx021871-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
abx021872-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
abx021873-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
abx021882-1mg | Abbexa | 1 mg | EUR 1178.4 |
HIV-1 p24 Antibody |
|||
abx021883-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
abx021886-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
abx021887-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
abx021888-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
abx023027-1ml | Abbexa | 1 ml | EUR 693.6 |
HIV-1 p24 Antibody |
|||
abx023925-1mg | Abbexa | 1 mg | EUR 828 |
HIV-1 p24 Antibody |
|||
abx023926-1mg | Abbexa | 1 mg | EUR 828 |
HIV-1 p24 |
|||
E5-00024 | EnoGene | 1mg | EUR 1152 |
HIV-1 p24 |
|||
E62H002 | EnoGene | 100ug | EUR 458.4 |
HIV-1 p24 |
|||
ant-152 | ProSpec Tany | 0.5mg | EUR 275 |
Description: Mouse Anti HIV-1 p24 |
HIV-1 p24 |
|||
hiv-006 | ProSpec Tany | 100µg | EUR 130 |
Description: Recombinant HIV-1 p24 |
HIV-1 tat recombinant antigen |
|||
00110-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 tat recombinant antigen |
|||
00110-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 gag recombinant antigen |
|||
8934 | Virostat | 100 ug | EUR 542.86 |
Description: This is HIV-1 gag recombinant antigen for ELISA,WB. |
HIV-1 nef recombinant antigen |
|||
8941 | Virostat | 100 ug | EUR 477.6 |
Description: This is HIV-1 nef recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen, |
|||
00170-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen, |
|||
00170-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen |
|||
8908 | Virostat | 100 ug | EUR 673.36 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
|||
8933 | Virostat | 100 ug | EUR 477.6 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
|||
9000 | Virostat | 100 ug | EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
|||
9001 | Virostat | 100 ug | EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen. |
|||
00170-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 gp41 recombinant antigen. |
HIV p24 Antibody |
|||
abx021867-1mg | Abbexa | 1 mg | EUR 1612.8 |
HIV p24 Antibody |
|||
abx021868-1mg | Abbexa | 1 mg | EUR 1612.8 |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
|||
00168-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
|||
00168-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen. |
|||
00168-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p24 Antibody (HRP) |
|||
abx023029-1ml | Abbexa | 1 ml | EUR 886.8 |
HIV-1 p24 Antibody [8G9] |
|||
PM-6335-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] |
|||
PM-6335-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
|||
PM-6585-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
|||
PM-6585-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody (FITC) |
|||
abx021884-100ug | Abbexa | 100 ug | EUR 886.8 |
HIV-1 p24 Antibody (FITC) |
|||
abx023026-1ml | Abbexa | 1 ml | EUR 678 |
HIV 1 / 2 p24 Antibody |
|||
abx021866-1mg | Abbexa | 1 mg | EUR 1212 |
HIV 1 / 2 p24 Antibody |
|||
abx021890-1mg | Abbexa | 1 mg | EUR 1212 |
HIV-1 p24 Antibody (Biotin) |
|||
abx023028-1ml | Abbexa | 1 ml | EUR 794.4 |
HIV 1 envelope recombinant antigen |
|||
00176-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 envelope recombinant antigen |
|||
00176-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
Polyclonal HIV-1 p24 Antibody |
|||
APR11116G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIV-1 p24 . This antibody is tested and proven to work in the following applications: |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 p24 gag |
|||
hiv-123 | ProSpec Tany | 100µg | EUR 165 |
Description: Recombinant HIV-I p24 gag |
HIV-1 p24 His |
|||
hiv-159 | ProSpec Tany | 5µg | EUR 60 |
Description: Recombinant HIV-1 p24 His Tag |
HIV-1 gp41 Long recombinant antigen, |
|||
00171-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 gp41 Long recombinant antigen, |
|||
00171-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 gp41 Long recombinant antigen. |
|||
00171-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 p24 24kDa |
|||
hiv-155 | ProSpec Tany | 2µg | EUR 60 |
Description: Recombinant HIV-1 p24 , 24kDa |
ToX Antigen (P24,GRA1) |
|||
E61Y00305 | EnoGene | 1mg | EUR 840 |
HIV-1 p24 Paired |
|||
ant-772 | ProSpec Tany | 100µg | EUR 200 |
Description: Mouse Anti HIV-1 p24 Paired |
HIV-1 p24 Protein |
|||
20-abx261886 | Abbexa |
|
|
HIV-1 p24 Protein |
|||
abx169032-1mg | Abbexa | 1 mg | EUR 661.2 |
HIV-1 p24 Protein |
|||
abx061424-05mg | Abbexa | 0.5 mg | EUR 886.8 |
HIV-1, p24 Protein |
|||
abx069857-1mg | Abbexa | 1 mg | EUR 1888.8 |
HIV-1 Gag p24 |
|||
05-005 | Sceti | 50 ug | EUR 434.4 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
HIV-1 Gag p24 |
|||
05-006 | Sceti | 250 ug | EUR 1154.4 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
Recombinant HIV-1 p24 |
|||
7-07603 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24 |
|||
7-07604 | CHI Scientific | 500µg | Ask for price |
Recombinant HIV-1 p24 |
|||
7-07605 | CHI Scientific | 1000µg | Ask for price |
HIV 1 p24 Protein |
|||
abx060589-1mg | Abbexa | 1 mg | EUR 1545.6 |
HIV Type-1 p24 Antibody |
|||
V2344-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
|||
V2344-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
|||
V2344CF488-100T | NSJ Bioreagents | 100 Tests | EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
|||
V2344SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
|||
00169-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV type 1 P24 |
|||
DAG1520 | Creative Diagnostics | 100 µg | EUR 972 |
HIV 1, 2 envelope recombinant antigen |
|||
00175-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV 1, 2 envelope recombinant antigen |
|||
00175-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV-1 reverse transcriptase recombinant antigen |
|||
00198-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 reverse transcriptase recombinant antigen. |
HIV-1 reverse transcriptase recombinant antigen |
|||
00198-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 reverse transcriptase recombinant antigen. |
HIV-1 reverse transcriptase recombinant antigen. |
|||
00198-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 reverse transcriptase recombinant antigen. |
HIV-1 p24 Antibody [8G9] (HRP) |
|||
PM-6335-HRP-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (HRP) |
|||
PM-6335-HRP-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (HRP) |
|||
PM-6585-HRP-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (HRP) |
|||
PM-6585-HRP-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (biotin) |
|||
PM-6335-biotin-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (biotin) |
|||
PM-6335-biotin-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (biotin) |
|||
PM-6585-biotin-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (biotin) |
|||
PM-6585-biotin-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody |
|||
abx411336-02mg | Abbexa | 0.2 mg | EUR 710.4 |
Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody |
|||
abx412988-2ml | Abbexa | 2 ml | EUR 727.2 |
HIV-2 gp32 recombinant antigen |
|||
00173-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp32 recombinant antigen |
|||
00173-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp36 recombinant antigen |
|||
8911 | Virostat | 100 ug | EUR 673.36 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
|||
8949 | Virostat | 100 ug | EUR 529.8 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
|||
9003 | Virostat | 100 ug | EUR 484.13 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp32 recombinant antigen. . |
|||
00173-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-2 gp32 recombinant antigen. . |
Polyclonal HIV-1 p24 Antibody [7F4] |
|||
APR11117G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Mouse that recognizes and binds to Human HIV-1 p24 [7F4] . This antibody is tested and proven to work in the following applications: |
HIV-1 p24, His tag |
|||
E410A26-20 | EnoGene | 20μg | EUR 520.8 |
HIV-1 p24 Clone 91 |
|||
ant-747 | ProSpec Tany | 0.5mg | EUR 275 |
Description: Mouse Anti HIV-1 p24, Clone-91 |
HIV-1 p24 Clone 80 |
|||
ant-748 | ProSpec Tany | 0.5mg | EUR 275 |
Description: Mouse Anti HIV-1 p24, Clone-80 |
HIV type O envelope antigen |
|||
00178-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV type O envelope antigen |
|||
00178-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV 2 gp36 envelope antigen |
|||
00180-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 gp36 envelope antigen |
|||
00180-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
|||
00175-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV-1 p24 Mouse mAb |
|||
E2210014-1D1 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
HIV-1 p24 Mouse mAb |
|||
E2210014-1F8 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
HIV-1 p24 Mouse mAb |
|||
E2210014-5B9 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
Mouse anti HIV-1 p24 McAb |
|||
E62H00502 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
Mouse anti HIV-1 p24 McAb |
|||
E62H00502a | EnoGene | 1mg | EUR 1250 |
Description: Available in various conjugation types. |
Mouse anti HIV-1 p24 McAb |
|||
E62H00503 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
Mouse anti HIV-1 p24 McAb |
|||
E62H00503a | EnoGene | 1mg | EUR 1250 |
Description: Available in various conjugation types. |
HIV-1 p24 Core Protein |
|||
20-abx260141 | Abbexa |
|
|
Rabbitt anti HIV-1 p24 PcAb |
|||
E62H00501 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
Rabbitt anti HIV-1 p24 PcAb |
|||
E62H00501a | EnoGene | 1mg | EUR 1250 |
Description: Available in various conjugation types. |
Mouse antibody for HIV-1 p24 |
|||
1941 | Virostat | 100 ug | EUR 399.3 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
|||
1946 | Virostat | 100 ug | EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
|||
1947 | Virostat | 100 ug | EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
|||
1948 | Virostat | 100 ug | EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
|||
1949 | Virostat | 100 ug | EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Recombinant HIV-1 p24 Core |
|||
7-07597 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24 Core |
|||
7-07598 | CHI Scientific | 500µg | Ask for price |
Recombinant HIV-1 p24 Core |
|||
7-07599 | CHI Scientific | 1000µg | Ask for price |
HIV-1 p24 Core, (Recombinant) |
|||
22060211-1 | Bio-WORLD | 100 µg | EUR 264.47 |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
Recombinant HIV-1 p24 , 24kDa |
|||
7-07621 | CHI Scientific | 2µg | Ask for price |
Recombinant HIV-1 p24 , 24kDa |
|||
7-07622 | CHI Scientific | 10µg | Ask for price |
Recombinant HIV-1 p24 , 24kDa |
|||
7-07623 | CHI Scientific | 100µg | Ask for price |
HIV-1 p24 Recombinant Protein |
|||
53-341 | ProSci | 0.01 mg | EUR 789.9 |
Description: HIV-1 p24 Recombinant Protein |
QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA) |
|||
VPK-108-H | Cell Biolabs | 96 assays | EUR 866.4 |
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation. |
QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA) |
|||
VPK-108-H-5 | Cell Biolabs | 5 x 96 assays | EUR 3560.4 |
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation. |
HIV type 1 P24 [GST] |
|||
DAG1516 | Creative Diagnostics | 100 µg | EUR 774 |
HIV type 1 P24 [His] |
|||
DAG1518 | Creative Diagnostics | 100 µg | EUR 774 |
HIV type 1 P24 [His] |
|||
DAG1799 | Creative Diagnostics | 50 ug | EUR 2017.2 |
HIV type 1 P24 [His] |
|||
DAG2375 | Creative Diagnostics | 100 µg | EUR 868.8 |
HIV type 1 P24 [His] |
|||
DAG2377 | Creative Diagnostics | 100 µg | EUR 868.8 |
HIV type 1 p24 [FITC] |
|||
DAGH004 | Creative Diagnostics | 50 Tests | EUR 1112.4 |
HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
00112-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 p24 Immune Complex Dissociation Kit |
|||
Z7040009 | Biochain | 1 kit | EUR 122 |
HIV type 1 P24 [Biotin] |
|||
DAG1519 | Creative Diagnostics | 100 µg | EUR 972 |
HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
00113-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 tat recombinant antigen full length 15 kDa |
|||
00110-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV -2 env gp36 recombinant antigen |
|||
00179-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV -2 env gp36 recombinant antigen |
|||
00179-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV p24 Mouse mAb |
|||
E2210005-10E7 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
HIV-1 gag p17, p24 Protein |
|||
20-abx260277 | Abbexa |
|
|
HIV-1 p24, 24 kDa Protein |
|||
20-abx263118 | Abbexa |
|
|
Recombinant HIV-1 gag p17, p24 |
|||
7-07675 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 gag p17, p24 |
|||
7-07676 | CHI Scientific | 500µg | Ask for price |
Recombinant HIV-1 gag p17, p24 |
|||
7-07677 | CHI Scientific | 1000µg | Ask for price |
HIV-1 gag p17, p24 (Recombinant) |
|||
22060195-1 | Bio-WORLD | 100 µg | EUR 264.47 |
HTLV-I p24 core recombinant antigen |
|||
00204-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HLTV-I p24 core recombinant antigen. |
HTLV-I p24 core recombinant antigen |
|||
00204-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HLTV-I p24 core recombinant antigen. |
HLTV-I p24 core recombinant antigen. |
|||
00204-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: HLTV-I p24 core recombinant antigen. |
HIV-1 p24 Core, Sf9 Protein |
|||
20-abx260012 | Abbexa |
|
|
Feline Immunodeficiency Virus p24 gag Antigen (FIV p24 gag) Antibody |
|||
abx413943-025mg | Abbexa | 0.25 mg | EUR 811.2 |
Mouse Monoclonal Anti- HIV-1 p24 IgG |
|||
AB-15210 | Alpha Diagnostics | 100 ug | EUR 416.4 |
Recombinant HIV-1 p24 His Tag |
|||
7-07606 | CHI Scientific | 5µg | Ask for price |
Recombinant HIV-1 p24 His Tag |
|||
7-07607 | CHI Scientific | 20µg | Ask for price |
Recombinant HIV-1 p24 His Tag |
|||
7-07608 | CHI Scientific | 1mg | Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
|||
7-07602 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
|||
7-07600 | CHI Scientific | 2µg | Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
|||
7-07601 | CHI Scientific | 10µg | Ask for price |
Recombinant Feline Immunodeficiency Virus p24 Antigen |
|||
E41H077 | EnoGene | 100ug | EUR 395 |
HIV-1 p24, Biotin Labeled Protein |
|||
20-abx260358 | Abbexa |
|
|
Recombinant HIV-1 p24 Protein [His] |
|||
VAng-0527Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: HIV type 1 P24 Antigen, recombinant protein from insect cell expression system. |
HIV-1 gag p24 IIIB Protein |
|||
abx060586-05mg | Abbexa | 0.5 mg | EUR 1128 |
Recombinant HIV-1 p24, Biotin Labeled |
|||
7-07612 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24, Biotin Labeled |
|||
7-07613 | CHI Scientific | 500µg | Ask for price |